CharuAgrawalMD

Internal Medicine • Houston, TX

Hospice & Palliative Medicine

Oncologic Palliative Care Physician at the Dan L Duncan Comprehensive Cancer Center

Join to view full profile

Dr. Agrawal is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Agrawal's full profile

Already have an account?

Office
7200 Cambridge St
Houston, TX 77030
Phone+1 713-798-3750

Fax+1 713-798-4693

Education & Training

University of Texas M D Anderson Cancer CenterFellowship, Hospice and Palliative Medicine, 2017
MedStar Health/Georgetown University HospitalResidency, Internal Medicine, 2013 - 2016
Texas A&M; Health Science Center College of MedicineClass of 2013

Certifications & Licensure

TX State Medical License 2017 - 2025
DC State Medical License 2013 - 2016
VA State Medical License 2013 - 2016
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hospice and Palliative Medicine

Publications & Presentations

PubMed

130 citations
Transmission event of SARS-CoV-2 delta variant reveals multiple vaccine breakthrough infections.
Timothy Farinholt, Harsha Doddapaneni, Xiang Qin, Vipin Kumar Menon, Qingchang Meng
BMC Medicine. 2021-10-01
14 citations
Transmission event of SARS-CoV-2 Delta variant reveals multiple vaccine breakthrough infections
Timothy Farinholt, Harshavardhan Doddapaneni, Xiang Qin, Vipin Kumar Menon, Qingchang Meng
Medrxiv. 2021-07-04
1 citations
Mother Tongue.
Charu Agrawal, Daniel Epner
JAMA Oncology. 2017-11-01

Lectures

Dynamic monitoring of circulating tumor DNA next-generation gene sequencing as a predictive biomarker of response and progression-free survival after pembrolizumab mon...
2019 ASCO Annual Meeting - 6/1/2019
New Targets: Time To Get Excited?
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
A phase 1b/2a, multi-center, open-label study to evaluate the safety and efficacy of combination treatment with MEDI0457 (INO-3112) and durvalumab (MEDI4736) in patien...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

Best of Momentum in 2020December 31st, 2020
Cancer and Cannabis: What Patients Need to KnowSeptember 9th, 2020